

1 **Title:** Risk factors for illness severity among pregnant women with confirmed SARS-CoV-2
2 infection – Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and
3 territorial health departments, March 29, 2020 -January 8, 2021

4 **Authors:** Romeo R. Galang, CDC COVID-19 Response, Centers for Disease Control and
5 Prevention, Atlanta, Georgia, USA; Suzanne M. Newton, CDC COVID-19 Response, Centers for
6 Disease Control and Prevention, Atlanta, Georgia, USA; Kate R. Woodworth, CDC COVID-19
7 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Isabel Griffin, CDC
8 COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Titilope
9 Oduyebo, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta,
10 Georgia, USA; Christina L. Sancken, CDC COVID-19 Response, Centers for Disease Control and
11 Prevention, Atlanta, Georgia, USA; Emily O’Malley Olsen, CDC COVID-19 Response, Centers for
12 Disease Control and Prevention, Atlanta, Georgia, USA; Kathy Aveni, Division of Family Health
13 Services, New Jersey Department of Health, Trenton, New Jersey, USA; Heather Wingate,
14 Communicable and Environmental Disease and Emergency Preparedness, Tennessee Department
15 of Health, Nashville, Tennessee, USA; Hanna Shephard, Bureau of Family Health and Nutrition,
16 Massachusetts Department of Public Health, Boston, Massachusetts, USA; Chris Fussman,
17 Maternal and Child Health Epidemiology Section, Michigan Department of Health and Human
18 Services, Lansing, Michigan, USA; Zahra S. Alaali, Division of Epidemiology, New York State
19 Department of Health, Albany, New York, USA; Samantha Siebman, Emerging Infections Program,
20 Minnesota Department of Health, St. Paul, Minnesota, USA; Umme-Aiman Halai, Acute
21 Communicable Disease Control Program, Los Angeles County Department of Public Health, Los
22 Angeles, California, USA; Camille Delgado Lopez, Division of Children with Special Medical Needs,
23 Puerto Rico Department of Health, San Juan, Puerto Rico, Puerto Rico; Jerusha Barton,
24 Epidemiology Division, Georgia Department of Public Health, Atlanta, GA, USA; Mamie Lush,

25 Division of Public Health, Nebraska Department of Health and Human Services, Lincoln,
26 Nebraska, USA; Paul H. Patrick, Perinatal and Reproductive Health Division, Oklahoma State
27 Department of Health, Oklahoma City, Oklahoma, USA; Levi Schlosser, Division of Disease
28 Control, North Dakota Department of Health, Bismarck, North Dakota, USA; Ayomide Sokale,
29 Division of Maternal, Child and Family Health, Philadelphia Department of Public Health,
30 Philadelphia, Pennsylvania, USA; Ifrah Chaudhary, Division of Disease Prevention and Control,
31 Houston Health Department, Houston, Texas, USA; Bethany Reynolds, Bureau of Epidemiology,
32 Pennsylvania Department of Health, Pittsburgh, Pennsylvania, USA; Similoluwa Sowunmi, Center
33 for Family Health, California Department of Public Health, Sacramento, California, USA; Nicole
34 Gaarenstroom, Nevada High Sierra Area Health Education Center, Reno, Nevada, USA; Jennifer S.
35 Read, Infectious Disease Epidemiology, Vermont Department of Health, Burlington, Vermont,
36 USA and Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; Sarah
37 Chicchelly, Infectious Disease Epidemiology and Response, Kansas Department of Health and
38 Environment, Topeka, Kansas, USA; Leah de Wilde, Epidemiology Division, US Virgin Islands
39 Department of Health, Christiansted, St. Croix, United States Virgin Islands; Eduardo Azziz-
40 Baumgartner, CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta,
41 Georgia, USA; Aron J. Hall, CDC COVID-19 Response, Centers for Disease Control and
42 Prevention, Atlanta, Georgia, USA; Van T. Tong, CDC COVID-19 Response, Centers for Disease
43 Control and Prevention, Atlanta, Georgia, USA; Sascha Ellington, CDC COVID-19 Response,
44 Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Suzanne M. Gilboa, CDC
45 COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; CDC
46 COVID-19 Response Pregnancy and Infant Linked Outcomes Team

47 **Keywords:** SARS-CoV-2, COVID-19, pregnancy, illness severity, risk factors

48 **Running title:** Pregnancy COVID-19 severity risk factors

49 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not
50 necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).

51 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
52 www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted
53 work; no financial relationships with any organizations that might have an interest in the submitted
54 work in the previous three years; no other relationships or activities that could appear to have
55 influenced the submitted work.

56 **Corresponding author:** Romeo R. Galang, MD MPH; U.S. Centers for Disease Control and
57 Prevention; 4770 Buford Highway NE, Mailstop S 107-2, Atlanta, GA 30341;
58 eocevent397@cdc.gov; Fax: 404-471-2509; Phone: 404-639-6387

59 **Alternate corresponding author:** Sascha Ellington, PhD; U.S. Centers for Disease Control and
60 Prevention; 4770 Buford Highway NE, Mailstop S 107-2, Atlanta, GA 30341;
61 eocevent397@cdc.gov; Fax: 770-471-8650; Phone: 770-488-6037

62 **Word Count: Abstract:** 228; **Main Text:** 1,796 of 3000

63 **Summary:** Among pregnant women with COVID-19, older age and underlying medical conditions
64 were risk factors for increased illness severity. These findings can be used to inform pregnant
65 women about their risk for severe COVID-19 illness and public health messaging.

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86

Abstract

Background: Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness compared with nonpregnant women. Data to assess risk factors for illness severity among pregnant women with COVID-19 are limited. This study aimed to determine risk factors associated with COVID-19 illness severity among pregnant women with SARS-CoV-2 infection.

Methods: Pregnant women with SARS-CoV-2 infection confirmed by molecular testing were reported during March 29, 2020–January 8, 2021 through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted from National Institutes of Health and World Health Organization criteria. Crude and adjusted risk ratios for moderate-to-severe or critical COVID-19 illness were calculated for selected demographic and clinical characteristics.

Results: Among 5,963 pregnant women with SARS-CoV-2 infection, moderate-to-severe or critical COVID-19 illness was associated with age 30–39 years, Black/Non-Hispanic race/ethnicity, healthcare occupation, pre-pregnancy obesity, chronic lung disease, chronic hypertension, cardiovascular disease, and pregestational diabetes mellitus. Risk of moderate-to-severe or critical illness increased with the number of underlying medical or pregnancy-related conditions.

Conclusions: Pregnant women with moderate-to-severe or critical COVID-19 illness were more likely to be older and have underlying medical conditions compared to pregnant women with asymptomatic infection or mild COVID-19 illness. This information might help pregnant women understand their risk for moderate-to-severe or critical COVID-19 illness and inform targeted public health messaging.

87 **Introduction**

88 Pregnant women with coronavirus disease 2019 (COVID-19) are at increased risk for severe illness
89 compared with nonpregnant women [1]. A limited number of studies have suggested that risk
90 factors for severe COVID-19 illness, such as older age and underlying medical conditions, might be
91 similar between pregnant and non-pregnant people; however, individual studies have been limited in
92 sample size, varied in sampling frame and inclusion criteria (e.g., inclusion of women with suspected
93 COVID-19 and/or those with confirmed COVID-19), and primarily reported on pregnant women
94 requiring hospitalization (including for childbirth) [2-4]. Additional information on risk factors for
95 severe COVID-19 illness are needed to inform discussions about risk for severe illness, to guide
96 public health messaging and to inform decision-making around resource allocation.

97 Public health jurisdictions report information, including pregnancy status, on confirmed and
98 probable COVID-19 cases to CDC through the National Notifiable Diseases Surveillance System
99 [5]. Through the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET),
100 health departments from 20 jurisdictions collected supplementary information on pregnancy
101 outcomes among women with SARS-CoV-2 infection confirmed by nucleic acid amplification
102 testing and reported during March 29, 2020–January 8, 2021 [6]. To determine risk factors associated
103 with COVID-19 illness severity, demographic and selected clinical characteristics were compared
104 between pregnant women with moderate-to-severe or critical illness and those with asymptomatic
105 infection or mild illness.

106 **Materials and Methods**

107 SET-NET is longitudinal surveillance of pregnant women and their infants to understand
108 the effects of emerging and reemerging threats [6]. Supplementary pregnancy-related information is
109 reported for women with laboratory confirmed SARS-CoV-2 infection (based on detection of
110 SARS-CoV-2 in a clinical specimen by nucleic acid amplification testing) during pregnancy through

111 the day of delivery in 2020 [7]. As of January 8, 2021, health departments from 20 jurisdictions
112 (California [excluding Los Angeles County], Georgia, Houston, Kansas, Los Angeles County,
113 Massachusetts, Michigan, Minnesota, Nebraska, Nevada, New Jersey, New York [excluding New
114 York City], North Dakota, Oklahoma, Pennsylvania [excluding Philadelphia], Philadelphia, Puerto
115 Rico, Tennessee, U.S. Virgin Islands, and Vermont) have contributed data [6]. Pregnancy status was
116 ascertained through routine COVID-19 case surveillance or through matching of reported cases
117 with other data sources (e.g., vital records, administrative data) to identify unreported pregnancy
118 status or verify pregnancy status. Data were abstracted using standard data elements; sources include
119 routine public health investigations, vital records, laboratory reports, and medical records. SET-NET
120 methodology has been previously described [6].

121 Criteria for illness severity (asymptomatic, mild, moderate-to-severe, or critical) were adapted
122 from National Institutes of Health and World Health Organization severity of illness categories
123 (Figure) [8-9]. Women were considered asymptomatic if reported as having an absence of symptoms
124 using a symptom status variable. Criteria were applied to classify severity using submitted data
125 (including symptoms, intensive care unit (ICU) admission, invasive ventilation, use of COVID-19
126 therapies, complications associated with COVID-19, and death). If data were not reported for an
127 outcome, the outcome was assumed not to have occurred. Crude risk ratios (RR) for moderate-to-
128 severe or critical illness were calculated for selected demographic characteristics within age group,
129 race/ethnicity, health insurance type, healthcare worker status and selected clinical characteristics,
130 including diagnosis of underlying medical condition (pre-pregnancy obesity [body mass index ≥ 30
131 kg/m²], chronic lung disease, chronic hypertension, pregestational diabetes mellitus, cardiovascular
132 disease, and immunosuppression), trimester of SARS-CoV-2 infection, and diagnosis of pregnancy-
133 related condition (gestational diabetes and gestational hypertension) as reported through contact
134 tracing, vital statistics, or medical records, compared to selected referent groups [6]. We also

135 calculated crude risk ratios comparing risk of moderate-to-severe or critical illness among pregnant
136 women with any one condition (underlying medical or pregnancy-related condition), any two
137 conditions, and three or more conditions compared to those without report of any condition.
138 Adjusted risk ratios (aRR) and 95% CIs for moderate-to-severe or critical illness were estimated by
139 binomial regression with the log link function, accounting for age (in years) as a continuous variable.
140 Analyses were conducted using SAS (version 9.4; SAS Institute). This activity was reviewed by CDC,
141 determined to be a non-research, public health surveillance activity, and was conducted consistent
142 with applicable federal law and CDC policy [10].

143 **Results**

144 During March 29–January 8, 2021, data for 10,996 pregnant women with confirmed SARS-
145 CoV-2 infection were submitted to SET-NET. Data for 5,033 (45.8%) women were insufficient for
146 categorizing illness severity. The remainder of this report focuses on 5,963 (54.2%) pregnant women
147 with SARS-CoV-2 infection and sufficient information to categorize illness severity.

148 Most women were aged 20-39 years (90.8%), 44.9% were Hispanic or Latina (Hispanic)
149 ethnicity, and 55.7% had Medicaid (Table 1). At least one underlying medical condition was reported
150 for 1,827 (35.3%) women, with pre-pregnancy obesity (27.2%) most commonly reported.
151 Gestational diabetes was reported in 8.9% of women and gestational hypertension in 9.0%. Most
152 women had SARS-CoV-2 infection identified in the third (60.6%) or second (29.1%) trimester
153 (based on date of first positive test or symptom onset).

154 In crude analysis, pregnant women who were 30-34 years (RR=1.35, 95% CI: 1.03, 1.77) and
155 35-39 years of age (RR=1.44, 95% CI: 1.08, 1.90) were at an increased risk of moderate-to-severe or
156 critical illness compared to pregnant women who were <20 years of age. Pregnant women reported
157 as having a healthcare occupation (RR=1.34, 95% CI: 1.18, 1.53) were at an increased risk of
158 moderate-to-severe or critical illness compared to pregnant women who were not reported as being

159 in a healthcare occupation. Pregnant women with pre-pregnancy obesity (RR=1.32, 95% CI: 1.17,
160 1.48), chronic lung disease (RR=1.39, 95% CI: 1.16, 1.66), chronic hypertension (RR=1.37, 95% CI:
161 1.09, 1.74), cardiovascular disease (RR=1.54, 95% CI: (1.14, 2.08), pregestational diabetes mellitus
162 (RR=1.54, 95% CI: 1.20, 1.98), and gestational diabetes (RR=1.23, 95% CI: 1.04, 1.45) were at
163 increased risk of moderate-to-severe or critical illness compared to pregnant women without these
164 conditions.

165 Presence of any health condition (underlying medical or pregnancy-related health condition)
166 was associated with 25% increased risk (RR=1.25, 95% CI: 1.12, 1.40), two conditions was
167 associated with a 52% increased risk (RR=1.52, 95% CI: 1.31, 1.78), and three or more conditions
168 was associated with twice the risk (RR=2.13, 95% CI: 1.70, 2.67) of moderate-to-severe or critical
169 illness compared to women without any reported conditions. Age younger than 29 years, age 30 to
170 39 years, race/ethnicity, health insurance type, trimester of SARS-CoV-2 infection,
171 immunosuppression, and gestational hypertension were not associated with increased risk of
172 moderate-to-severe or critical illness compared to the referent groups.

173 Adjusted risk ratios were similar to crude risk ratios with two exceptions. After adjustment
174 for age as a continuous variable, Black/Non-Hispanic race/ethnicity was associated with a 22%
175 increased risk (aRR=1.22, 95% CI: 1.04, 1.43) of moderate-to-severe or critical illness compared to
176 the referent group (White, Non-Hispanic race/ethnicity), and gestational diabetes was not found to
177 be associated with increased risk.

178 Discussion

179 In an analysis of a large cohort of pregnant women with SARS-CoV-2 infection reported from
180 health departments from 20 jurisdictions through SET-NET, age 30-39 years, Black/Non-Hispanic
181 race/ethnicity, being a healthcare worker, and presence of any underlying medical condition were
182 associated with increased risk of moderate-to-severe or critical illness. The number of underlying

183 medical or pregnancy-related conditions demonstrated an exposure-response relation with risk for
184 moderate-to-severe or critical illness. Data collection is ongoing, and findings may change as
185 additional data are collected and analyzed. Data are reported by health departments and can be
186 updated as new information becomes available. Enhanced efforts to improve reporting of clinical
187 data related to illness severity are ongoing.

188 These findings of association between older age, Black/Non-Hispanic race/ethnicity,
189 healthcare occupation, any underlying medical condition and increased risk of moderate-to-severe or
190 critical COVID-19 illness are similar to those observed among nonpregnant adults. There have been
191 few studies focused on risk factors for COVID-19 illness severity in pregnant women; those study
192 findings suggest similar associations with older age and medical comorbidities as seen in the general
193 adult population [2-4]. An association was not found with trimester of SARS-CoV-2 infection,
194 similar to findings from a recent systematic review and meta-analysis of SARS-CoV-2 infection in
195 pregnancy [4]. An association of Hispanic or Latina race/ethnicity with moderate-to-severe or
196 critical illness was not identified; however, Hispanic or Latina women represented half of all women
197 with moderate-to-severe or critical illness in this analysis.

198 The findings in this report are subject to at least four limitations. First, the clinical criteria for
199 classifying illness severity in this analysis were adapted for surveillance purposes from existing
200 frameworks and used severity indicators that were captured systematically, while other criteria may
201 not have been captured (e.g., respiratory rate and oxygen saturation on room air). Misclassification
202 of illness severity is possible, particularly when data to classify cases into moderate-to-severe or
203 critical illness categories are missing, which might bias towards a lower severity classification and
204 attenuate associations [11]. Similarly, data cannot distinguish between asymptomatic or pre-
205 symptomatic mild infection unless the individual subsequently reported for medical care and
206 information was available in a medical record. Additionally, women who were tested upon hospital

207 admission for delivery may have developed more severe symptoms later on that were not captured
208 by SET-NET. Among women with date of testing and outcome available, 26% were identified
209 within two days of delivery, which could reflect universal screening on admission. Second, a large
210 portion of women could not be categorized for illness severity due to insufficient information, and
211 testing and reporting might be more frequent among women with more severe illness. The ability to
212 detect differences in demographic characteristics between included and excluded women were
213 limited by a large portion of missing demographic information among excluded cases due to the
214 large surge of cases and limited capacity for complete data collection. Additionally, obtaining
215 accurate data to distinguish underlying medical conditions from pregnancy-related medical
216 conditions (e.g., diabetes vs gestational diabetes) depends on medical record abstraction. Potential
217 misclassification of underlying medical conditions and pregnancy-related medical conditions might
218 limit detection of an association with moderate-to-severe or critical illness. Medical record
219 abstraction of clinical information are ongoing, and statistical comparisons by illness severity should
220 be interpreted with caution. Third, while these data are population-based for the jurisdictions
221 included, they are not nationally representative and include a higher frequency of Hispanic and
222 Latina women compared with all women of reproductive age in national case surveillance data and
223 with provisional national 2020 data on births among women with COVID-19 during pregnancy [1,
224 12-13]. Fourth, relative to the proportion of women with SARS-CoV-2 infection in the second and
225 third trimesters of pregnancy, few women with first trimester infection have been reported to date.
226 This limits our ability to understand whether trimester of infection is associated with severity of
227 COVID-19 illness.

228 Despite these limitations, this report has several strengths, including the large size of the
229 population-based cohort, inclusion of both hospitalized and non-hospitalized pregnant women,
230 restriction of the study population to pregnant women with confirmed COVID-19, information to

231 describe risk factors for illness severity among pregnant women with COVID-19, and uniform
232 application of illness severity criteria.

233 Future research could further focus on clinical relevance of maternal COVID-19 illness
234 severity and outcomes among newborns, infants, and children. Additional follow-up data on SARS-
235 CoV-2 infection are needed to increase certainty of findings related to severity of COVID-19 illness
236 and timing of infection during pregnancy.

237 These data can help counsel pregnant women about their risk for moderate-to-severe or
238 critical COVID-19 illness and guide their choice of prevention strategies, target public health
239 messaging, and inform decisions around resource allocation. It is important that pregnant women
240 are informed of their increased risk for severe COVID-19 illness, the signs of severe COVID-19
241 illness, and strategies for prevention, including vaccination [14-16].

242 **Funding:** This study was performed as regular work of the Centers for Disease Control and
243 Prevention. This work is supported by the Epidemiology and Laboratory Capacity for Prevention
244 and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement (ELC CK19-1904) and
245 through contractual mechanisms, including the Local Health Department Initiative.

246 **Acknowledgments**

247 Joy Rende, Lindsey Sizemore, Elizabeth Harvey, Nicole D. Longcore, Nadia Thomas, Pauline
248 Santos, Deirdre Depew, Jamie N. Sommer, Claire McGarry, Ona Loper, Shannon Baack, Miguel
249 Valencia Prado, Leishla Nieves Ferrer, Mariam Marcano Huertas, Stephany Perez González,
250 Glorimar Meléndez Rosario, Marangelí Olán Martínez, Hilcon Agosto Rosa, Reynaldo Pérez Alices,
251 J. Michael Bryan, Cristina Meza, Victoria Sanon, Teri Willabus, Cynthia Carpentieri, Michael
252 Andrews, Skip Frick, Robin M. Williams, Samir Koirala, Tyler Faulkner, Shannon Lawrence, Erika
253 Fuchs, Celeste Illian, Elizabeth Wyckoff, Aasta D. Mehta, Patrick Nwachukwu, Lauren Orkis,
254 Richard Olney, Valorie Eckert, Barbara Warmerdam, Olga Barer, State, local, and territorial health

255 department personnel; U.S. clinical, public health, and emergency response staff members; CDC
256 Epidemiology and Surveillance Task Force, CDC Data Analytics and Modeling Task Force

257 **COVID-19 Pregnancy and Infant Linked Outcomes Team (PILOT)**

258 Jennifer Beauregard, CDC; Jason Hsia, CDC; Kellianne King, CDC; Jean Ko, CDC; Elizabeth
259 Lewis, CDC; Susan Manning, CDC; Varsha Neelam, CDC; Mirna Perez, CDC; Emily Petersen,
260 CDC; Megan Reynolds, CDC; Aspen Riser, CDC; Maria Rivera, CDC; Nicki Roth, CDC; Regina
261 Simeone, CDC; John Sims, CDC; Ashley Smoots, CDC; Margaret Snead, CDC; Penelope Strid,
262 CDC; Diana Valencia, CDC; Bailey Wallace, CDC; Tineka Yowe-Conley, CDC; Laura Zambrano,
263 CDC; Lauren Zapata, CDC; Amanda Akosa, Eagle Global Scientific; John F. Nahabedian III, Eagle
264 Global Scientific; Amitsingh Rathore, Eagle Global Scientific; Neha Shinde, Eagle Global Scientific;
265 Veronica Burkel, Eagle Medical; Dena Cherry, General Dynamics Informational Technology; Daniel
266 Chang, Oak Ridge Institute for Science and Education; Charise Fox, Oak Ridge Institute for Science
267 and Education; Emily Reeves, Oak Ridge Institute for Science and Education; Ayzsa Tannis, Oak
268 Ridge Institute for Science and Education; Susanna Trost, Oak Ridge Institute for Science and
269 Education

270 **Potential conflict of interests:** All authors have completed and submitted the International
271 Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No
272 potential conflicts of interest were disclosed. This work has not been published previously and is not
273 under consideration for publication elsewhere.

274

275

References

276 1. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of
277 Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status

- 278 — United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep*, **2020**;
279 69:1641–1647.
- 280 2. Di Martino D, Chiaffarino F, Patanè L, et al. Assessing risk factors for severe forms of
281 COVID-19 in a pregnant population: A clinical series from Lombardy, Italy. *Int J Gynaecol*
282 *Obstet*. Epub ahead of print. October 24, 2020 [cited 2021 Feb 16] Available from: doi:
283 10.1002/ijgo.13435.
- 284 3. Brandt JS, Hill J, Reddy A, et al. Epidemiology of coronavirus disease 2019 in pregnancy:
285 risk factors and associations with adverse maternal and neonatal outcomes. *Am J Obstet*
286 *Gynecol*. Epub ahead of print. September 25, 2020 [cited 2021 Feb 16] Available from: doi:
287 10.1016/j.ajog.2020.09.043.
- 288 4. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and
289 perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and
290 meta-analysis. *BMJ*, **2020**; 370:m3320.
- 291 5. Centers for Disease Control and Prevention – National Center for Immunization and
292 Respiratory Diseases – Information for Health Departments on Reporting Cases of
293 COVID-19. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-](https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html)
294 [pui.html](https://www.cdc.gov/coronavirus/2019-ncov/php/reporting-pui.html). Accessed December 21, 2020.
- 295 6. Woodworth KR, Reynolds MR, Burkel V, et al. A Preparedness Model for Mother–Baby
296 Linked Longitudinal Surveillance for Emerging Threats. *Matern Child Health J*, **2021** Jan
297 4:1–9.
- 298 7. Centers for Disease Control and Prevention – Office of Public Health Scientific Services –
299 Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5,
300 2020; Available from: [https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-](https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/)
301 [covid-19/case-definition/2020/08/05/](https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/). Accessed February 4, 2021.

- 302 8. National Institutes of Health – COVID-19 Treatment Guidelines Panel. Coronavirus
303 Disease 2019 (COVID-19) Treatment Guidelines. Available from:
304 <https://www.covid19treatmentguidelines.nih.gov/>. Accessed December 21, 2020.
- 305 9. World Health Organization – Clinical management of COVID-19: interim guidance.
306 Available from: <https://apps.who.int/iris/handle/10665/332196>. Accessed December 21,
307 2020.
- 308 10. Department of Health and Human Services – 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C.
309 Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq. Available from:
310 <https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/ohrpreulations.pdf>. Accessed
311 February 4, 2021.
- 312 11. Lipsitch M, Donnelly CA, Fraser C, et al. Potential biases in estimating absolute and relative
313 case-fatality risks during outbreaks. *PLoS Negl Trop Dis*, **2015**; 9:e0003846.
- 314 12. Centers for Disease Control and Prevention – National Center for Health Statistics –
315 Maternal and Infant Characteristics Among Women with Confirmed or Presumed Cases of
316 Coronavirus Disease (COVID-19) During Pregnancy. Available from:
317 <https://www.cdc.gov/nchs/covid19/technical-linkage.htm>. Accessed December 21, 2020.
- 318 13. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with
319 laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January
320 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep*, **2020**; 69:769–75.
- 321 14. Centers for Disease Control and Prevention – National Center for Immunization and
322 Respiratory Diseases – Symptoms of Coronavirus. Available from:
323 <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>. Accessed
324 December 21, 2020.

- 325 15. Centers for Disease Control and Prevention – National Center for Immunization and
326 Respiratory Diseases – Pregnancy, Breastfeeding, and Caring for Newborns. Available from:
327 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html/)
328 [breastfeeding.html/](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html/). Accessed February 8, 2021.
- 329 16. Centers for Disease Control and Prevention – National Center for Immunization and
330 Respiratory Diseases – Interim Clinical Considerations for Use of mRNA COVID-19
331 Vaccines Currently Authorized in the United States. Available from:
332 [https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html)
333 [considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fc](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html)
334 [ovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html). Accessed February
335 1, 2020.

336 **Figure. Criteria for categorizing severity of illness among pregnant women with SARS-CoV-2**
 337 **infection, Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET)**

Severity of Illness	Description of the surveillance categorization of severity of COVID-19 illness among pregnant women ^a
Critical	Defined as reported with complication of COVID-19: mechanical ventilation/intubation, ECMO, ICU admission, ARDS, respiratory failure, septic shock, or multiple organ dysfunction; COVID-19 listed as a cause of death
Moderate-to-Severe^b	Defined as reported with any of the following, and not meeting criteria for critical illness: <ul style="list-style-type: none"> • Symptoms of dyspnea/shortness of breath AND at least one of the following: fever or cough. • Receipt of oxygen therapy by nasal cannula or a high-flow oxygen device, pneumonia • Treatment for COVID-19 with remdesivir, convalescent plasma, hydroxychloroquine + azithromycin, hydroxychloroquine alone. Additional treatments may be included as evidence of disease severity, referring to NIH treatment guidelines.
Mild^c	Defined as symptomatic illness with at least one of the individual symptoms reported, and not meeting criteria for moderate-to-severe or critical illness □
Asymptomatic infection^d	Defined as reported as asymptomatic ^e (not just absence of reported symptoms) and not meeting criteria for mild, moderate-to-severe, or critical illness
Insufficient information	Defined as missing information needed to categorize into asymptomatic infection, mild, moderate-to-severe, or critical illness

338 Abbreviations: ARDS = acute respiratory distress syndrome, ECMO = extracorporeal membrane

339 oxygenation, ICU= intensive care unit

340 ^aAdapted from National Institutes of Health

341 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/> and World Health

342 Organization <https://www.who.int/publications/i/item/clinical-management-of-covid-19>.

343 ^bData considered in classification included systematically collected indicators of illness severity. A search was

344 performed to identify informative clinical data in free text notes; however, free text notes are not routinely

345 collected and are often missing. Ability to distinguish moderate and severe illness is limited by data which are

346 not routinely collected and highly likely to be missing from free text notes: respiratory rate, blood oxygen
347 saturation on room air.

348 ^eLimitations: persons with mild symptoms may not seek medical care. Unless a case interview was performed,
349 we will not have information on mild symptoms.

350 ^dLimitations include inability to distinguish between asymptomatic or pre-symptomatic mild infection unless
351 the individual reported for medical care and information was available in a medical record.

352 ^eResponse options for symptom status include (symptomatic, asymptomatic, and unknown).

353 <https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf>.

354 **Table 1. Risk ratios for moderate-to-severe or critical illness among pregnant women with SARS-CoV-2 infection during**
 355 **pregnancy compared to asymptomatic infection or mild illness for selected demographic and clinical characteristics,**
 356 **Surveillance for Emerging Threats to Mothers and Babies Network, 20 state, local, and territorial health departments, March 29,**
 357 **2020 -January 8, 2021 (n=5,963)^a**

	No. of women (%)			Risk Ratio	95% CI	Adjusted Risk Ratio	95% CI
	Total	Moderate-to-severe or critical illness	Asymptomatic infection or mild illness				
Total	5,963	1,379 (23.1)	4,584 (76.9)				
Age	[4215]	[1032]	[3183]				
<20	249 (5.9)	49 (4.8)	200 (6.3)	1	ref.	-	-
20-24	847 (20.1)	182 (17.6)	665 (20.9)	1.09	(0.82, 1.44)	-	-
25-29	1306 (31.0)	307 (29.8)	999 (31.4)	1.19	(0.91, 1.56)	-	-
30-34	1098 (26.1)	292 (28.3)	806 (25.3)	1.35	(1.03, 1.77)	-	-
35-39	577 (13.7)	163 (15.8)	414 (13.0)	1.44	(1.08, 1.90)	-	-
40 +	138 (3.3)	39 (3.8)	99 (3.1)	1.44	(1.00, 2.07)	-	-
Race/ethnicity	[4961]	[1171]	[3790]				
White, Non-Hispanic	1494 (30.1)	340 (29.0)	1154 (30.5)	1	ref.	1	ref.
Asian, Non-Hispanic	178 (3.6)	50 (4.3)	128 (3.4)	1.23	(0.96, 1.59)	1.27	(0.95, 1.68)
Black, Non-Hispanic	898 (18.1)	227 (19.4)	671 (17.7)	1.11	(0.96, 1.29)	1.22	(1.04, 1.43)
Hispanic or Latina	2225 (44.9)	526 (44.9)	1699 (44.8)	1.04	(0.92, 1.17)	0.92	(0.80, 1.05)
Multiple or other, Non-Hispanic	166 (3.4)	28 (2.4)	138 (3.6)	0.74	(0.52, 1.05)	1.02	(0.71, 1.46)
Health insurance	[3735]	[931]	[2804]				
Private	1451 (38.9)	342 (36.7)	1109 (39.6)	1	ref.	1	ref.
Medicaid	2079 (55.7)	545 (58.5)	1534 (54.7)	1.11	(0.99, 1.25)	1.13	(0.99, 1.29)
Other	130 (3.5)	26 (2.8)	104 (3.7)	0.85	(0.59, 1.21)	1.07	(0.75, 1.51)

Self-pay/none	75 (2.0)	18 (1.9)	57 (2.0)	1.02	(0.67, 1.54)	0.95	(0.61, 1.47)
Healthcare occupation	[3245]	[806]	[2439]				
No	2512 (77.4)	579 (71.8)	1933 (79.3)	1	ref.	1	ref.
Yes	733 (22.6)	227 (28.2)	506 (20.8)	1.34	(1.18, 1.53)	1.31	(1.14, 1.50)
Trimester of SARS-CoV-2 infection^c	[5100]	[1216]	[3884]				
First	525 (10.3)	123 (10.1)	402 (10.4)	1	ref.	1	ref.
Second	1486 (29.1)	379 (31.2)	1107 (28.5)	1.09	(0.91, 1.30)	1.01	(0.82, 1.24)
Third	3089 (60.6)	714 (58.7)	2375 (61.2)	1	(0.83, 1.17)	1.02	(0.84, 1.24)
Underlying medical condition^d	[5177]	[1144]	[4033]				
Any underlying medical condition	1827 (35.3)	498 (43.5)	1329 (33.0)	1.41	(1.28, 1.57)	1.48	(1.32, 1.67)
Obesity ^e	1407 (27.2)	373 (32.6)	1034 (25.6)	1.32	(1.17, 1.48)	1.29	(1.12, 1.48)
Chronic lung disease	318 (6.1)	102 (8.9)	216 (5.4)	1.39	(1.16, 1.66)	1.44	(1.19, 1.73)
Chronic hypertension	164 (3.2)	51 (4.5)	113 (2.8)	1.37	(1.09, 1.74)	1.35	(1.05, 1.73)
Diabetes mellitus (type 1 or type 2)	117 (2.3)	41 (3.6)	76 (1.9)	1.54	(1.20, 1.98)	1.57	(1.21, 2.04)
Cardiovascular disease	86 (1.7)	30 (2.6)	56 (1.4)	1.54	(1.14, 2.08)	1.46	(1.06, 2.02)
Immunosuppression	41 (0.8)	11 (1.0)	30 (0.7)	1.28	(0.76, 2.12)	1.49	(0.88, 2.53)
Pregnancy-related condition^d	[4470]	[995]	[3475]				
Gestational diabetes	447 (10.0)	119 (12.0)	328 (9.4)	1.23	(1.04, 1.45)	1.1	(0.90, 1.33)
Gestational hypertension	452 (10.1)	115 (11.6)	337 (9.7)	1.16	(0.98, 1.38)	1.11	(0.92, 1.35)
Number of conditions^f	[5337]	[1166]	[4171]				
None	3106 (58.2)	589 (50.5)	2517 (60.4)	1	ref.	1	ref.
Any 1 condition	1602 (30.0)	381 (32.7)	1221 (29.3)	1.25	(1.12, 1.40)	1.3	(1.13, 1.48)
Any 2 conditions	505 (9.5)	146 (12.5)	359 (8.6)	1.52	(1.31, 1.78)	1.59	(1.33, 1.89)
Any 3 or more conditions	124 (2.3)	50 (4.3)	74 (1.8)	2.13	(1.70, 2.67)	1.82	(1.39, 2.39)

358 ^aDuring March 29, 2020–January 8, 2021, data for 10,996 pregnant women with SARS-CoV-2 infection were submitted to SET-NET. Data for 5,033

359 (45.8%) women were insufficient for categorizing severity of illness.

360 ^bAdjusted for age as a continuous variable.

361 ^cTrimester of SARS-CoV-2 infection based on date of first positive test or symptom onset.

- 362 ^dReferent group: pregnant women without report of underlying medical condition or pregnancy-related condition, respectively.
- 363 ^ePregestational obesity defined as body mass index ≥ 30 kg/m².
- 364 ^fIncludes underlying medical conditions (pre-pregnancy obesity, chronic lung disease, chronic hypertension, diabetes mellitus (type 1 or type 2),
- 365 cardiovascular disease and immunosuppression) and pregnancy-related conditions (gestational diabetes and gestational hypertension